Biopharma

Capsugel®/ Lonza published a new podcast episode: For years, oral delivery of biologics has been viewed as impractical. But what...

Abstract Oxidation represents a key pathway for the chemical degradation of therapeutic monoclonal antibodies (mAbs), and chemical liabilities such as...

Biopharmaceutical excipients are the inactive substances added to biologic drug products to protect large, structurally fragile biomolecules, such as monoclonal...

GELITA has launched an ultra low endotoxin gelatin, specified at less than 10 endotoxin units (EU) per gram, for sensitive...

Messenger RNA (mRNA) is intrinsically unstable due to spontaneous 2'-hydroxyl-mediated phosphodiester hydrolysis, with degradation rates accelerating at pH below 5.0...

Abstract There is a growing demand in the subcutaneous delivery of monoclonal antibodies (mAbs) to reduce treatment burden for both...

Abstract In recent years, biologics-based modalities have increased significantly across various therapeutic areas. Monoclonal antibodies (mAbs) and emerging bioconjugates such...

Abstract The therapeutic landscape for biologics is rapidly transitioning from intravenous (IV) to subcutaneous (SC) administration, offering significant benefits in...

Abstract Building on growing evidence that ionizable lipids improve RNA delivery, in this work, we developed ionizable lipid/poly(lactic-co-glycolic acid) hybrid...

Abstract Preservatives are critical for preventing microbial contamination in multi-dose biologics, yet their compatibility with proteins poses a major challenge....